Hepatocellular Cancer
Conditions
Interventions
Group 1:Anlotinib, TACE after hepatectomy 1 month later
Group 2:TACE treatment after hepatectomy 1 month later
Sponsors
Shanghai Public Health Clinical Center
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed liver cancer patients, 18-80 years old, liver function Child A grade, ECOG score 0-1 points; 2. No gross vascular or cholangiocarcinoma, no extrahepatic metastasis, postoperative pathology confirmed poor differentiation and / or MVI in hepatocellular carcinoma; 3. The tumor RO is completely removed.
Exclusion criteria
Exclusion criteria: 1. Patients who have been treated or relapsed with liver cancer, younger than 18 years old or older than 80 years old; 2. Liver function Child B grade and above, creatinine higher than the upper limit of normal, eGFR less than 90, ECOG score of 2 or more, cardiopulmonary function and other clear surgical contraindications; 3. There is no effective control of hypertension, postoperative incision healing is not good, surgical wounds are caused by biliary or infection due to effusion and drainage can not be removed; 4. The tumor can not be removed by RO, there are macroscopic blood vessels or cholangiocarcinoma, there is extrahepatic metastasis; 5. Postoperative pathology confirmed high differentiation of hepatocellular carcinoma or non-hepatocellular carcinoma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AFP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver Function;Crea;eGFR; | — |
Countries
China
Contacts
Public ContactHuang Yangqing
Shanghai Public Health Clinical Center
Outcome results
None listed